Clinical trials: COVID-19 Booster
Coronavirus Disease (COVID-19)
A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)
TAK-019 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-019 can protect people from Covid-19 and to check for side effects from TAK-019 for participants who will…
- Trial name
- NCT05299359
- Testing
- TAK-019
- Where
- 2 sites in Japan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Takeda
Influenza, COVID-19
Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine
This study investigates healthcare workers' attitudes towards co-administering COVID-19 and seasonal influenza vaccines, a method supported globally for its efficiency and potential to lessen healthcare burdens.
- Trial name
- CoVFlu (NCT05781191)
- Testing
- COMIRNATY
- Where
- Italy
- Volunteers
- 8,231 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
COVID-19, Vaccines
Information Provision and Consistency Framing to Increase COVID-19 Booster Uptake
This study investigates different ways to elevate intentions to get the COVID-19 booster via text-based reminders, including providing information about the booster and leveraging the consistency principle.
- Trial name
- NCT05586178
- Testing
- Reminder that facilitates action, Consistency framing, Information provision about the uniqueness of the bivalent booster
- Where
- United States
- Volunteers
- 177,720 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
SARS-CoV-2 Infection
Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally.
An open label, randomized, dose comparison, sequential cohorts study design in healthy volunteers (young adults) is a frequently used design in vaccine Phase 1 studies.
- Trial name
- NCT05385991
- Testing
- ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)
- Where
- 6 sites in Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- ACM Biolabs
COVID-19, Vaccines
Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers
The immunogenicity and safety of AdCLD-CoV19-1 OMI (5.0x10^10 VP (0.5 mL)/dose/Vial) administered as a booster in healthy adults aged 19 years old and above will be evaluated.
- Trial name
- COVID-19 (NCT05993325)
- Testing
- AdCLD-CoV19-1 OMI, Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)
- Where
- 17 sites in Philippines, South Korea
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Cellid Co., Ltd.